Figure A5. Incremental costs and effectiveness by treatment strategy for solid tumour patients who can take quinolone (using a baseline risk of neutropenic sepsis for one course of chemotherapy of 34.41%).

Figure A5Incremental costs and effectiveness by treatment strategy for solid tumour patients who can take quinolone (using a baseline risk of neutropenic sepsis for one course of chemotherapy of 34.41%)

From: Appendix A, A cost-utility analysis of primary and secondary prophylaxis with G(M)-CSF and/or quinolones for the prevention of neutropenic sepsis

Cover of Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients
Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients.
NICE Clinical Guidelines, No. 151.
National Collaborating Centre for Cancer (UK).
Copyright © National Collaborating Centre for Cancer, 2012.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.